Oxycodone/Naloxone Stada (Naloxone, Oxycodone)

Oxycodone/Naloxone Stada is used in the management of moderate to severe pain where opioid therapy is required and constipation is a concern.

• Chronic non‑cancer pain: provides analgesia while mitigating opioid‑induced bowel dysfunction.
• Cancer‑related pain: delivers strong pain relief with reduced risk of constipation.
• Post‑operative pain: controls acute pain after surgery and helps maintain bowel function.
• Pain in opioid‑tolerant patients: offers effective analgesia with a built‑in antagonist to limit excess opioid effects.

• The combination works by delivering oxycodone, a µ‑opioid receptor agonist that produces analgesia, together with naloxone, a peripheral µ‑opioid receptor antagonist that remains largely inactive systemically when taken orally but blocks opioid receptors in the gastrointestinal tract, thereby reducing constipation while preserving central pain relief.

Side effects are reported for both components of the combination, with the naloxone component primarily influencing gastrointestinal tolerance.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Constipation: reduced bowel movements despite naloxone.
• Dizziness: light‑headed sensation.
• Somnolence: sleepiness or fatigue.
• Dry mouth: reduced salivation.
• Headache: mild cranial pain.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing, potentially life‑threatening.
• Severe hypotension: marked drop in blood pressure.
• Acute opioid withdrawal: agitation, sweating, vomiting when naloxone effect dominates.
• Hepatic dysfunction: elevated liver enzymes.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Seizures: rare convulsive episodes.

When prescribing Oxycodone/Naloxone Stada, clinicians should consider patient history and monitor for adverse reactions.

• Assess renal and hepatic function: adjust use if impairment is present.
• Evaluate gastrointestinal history: patients with severe bowel obstruction may need alternative therapy.
• Monitor for signs of opioid dependence or abuse: use with caution in at‑risk individuals.
• Avoid concurrent strong CYP3A4 inhibitors: may increase oxycodone levels.
• Educate patients on proper dosing and risks: ensure understanding of when to seek medical help.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Oxycodone/Naloxone Stada can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise oxycodone concentrations and increase toxicity risk.
• CNS depressants (e.g., benzodiazepines, barbiturates, alcohol): additive sedation and respiratory depression.
• MAO inhibitors: can precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase oxycodone exposure.
• Diuretics: can enhance hypotensive effects.
• Anticholinergics: may worsen constipation despite naloxone component.